Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab 3 mg/kg versus 10 mg/kg in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON42128Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ipilimumab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Radiographic progression-free survival. Started Apr 2015; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON42128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42128.